General

Cell Line
hPSCreg name	GENEAe014-A
Cite as: When citing this cell line, please use the hPSCreg name (see Naming Tool ) and the corresponding Research Resource ID (RRID).	GENEAe014-A (RRID:CVCL_9038)
Alternative name(s)	GENEA029
Cell line type	Human embryonic stem cell (hESC)
Similar lines	No similar lines found.
Last update	22nd March 2021
User feedback show/hide	Written by on Delete No feedback available yet. Login to share your feedback, experiences or results with the research community.
Provider
Generator	Genea (GENEA) Contact: Biocells
Owner	Biocells
Distributors	Biocells
External Databases
BioSamples	SAMEA104012532
Cellosaurus	CVCL_9038
Wikidata	Q54835595
General Information
Publications	Bradley CK et al. Cell lines from morphologically abnormal discarded IVF embryos are typically euploid and unaccompanied by intrachromosomal aberrations. Reproductive biomedicine online. 2014 Jun;28(6):780-8. McQuade LR et al. Proteomics of Huntington's disease-affected human embryonic stem cells reveals an evolving pathology involving mitochondrial dysfunction and metabolic disturbances. Journal of proteome research. 2014 Dec 5;13(12):5648-59.
* Is the cell line readily obtainable for third parties?	Yes Research use: allowed Clinical use: allowed Commercial use: allowed

Donor Information

General Donor Information
Sex	female
Phenotype and Disease related information (Donor)
Diseases	No disease was diagnosed.
External Databases (Donor)
BioSamples	SAMEA104012533

Ethics

Was the embryo established purely for research purposes?	No
Have both parents consented to the use of the embryo for ESC derivation?	Yes
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived?	Yes
Was the consent voluntarily given?	Yes
Alternatives to consent are available?	Yes
Alternatives to consent	IVF patients gave consent for investigations of clinically unsuitable embryos as part of their clinical cycle. This is a clinical process, independent of research. hESC were derived from embryonic outgrowth cells, originally developed for karyotyping, not from embryos and fully informed consent was granted. Multiple documents could not be added here so will send via email.
Alternative consent approval number
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised.	pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells?	Yes
* Does consent expressly prevent the derivation of pluripotent stem cells?	No
How may genetic information associated with the cell line be accessed?
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample?	No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions?	Yes
Name of accrediting authority involved?	GeneaHREC
Approval number	meeting 13/9/2005

hESC Derivation

Date of derivation	2009-02-24
Supernumerary embryos from IVF treatment?	Yes Separation of research and IVF treatment? Yes
PGD Embryo?	No

Culture Conditions

Medium

Other medium: Base medium: DMEM/F-12 Main protein source: Fetal bovine serum Serum concentration: 20 % Supplements Supplement Amount Unit FGF 50ng/mL %

Characterisation

Analysis of Undifferentiated Cells

Marker Expression

Marker	Expressed	Immunostaining	RT-PCR	Flow Cytometry	Enzymatic Assay	Expression Profiles
NANOG	Yes
POU5F1 (OCT-4)	Yes
SSEA-4	Yes
TRA 1-60	Yes

Other pluripotency tests used

Teratoma positive, Alkaline Phosphatase stain positive.

Differentiation Potency

Endoderm

Endoderm
Ont Id: UBERON_0000925

Mesoderm

Mesoderm
Ont Id: UBERON_0000926

Ectoderm

Ectoderm
Ont Id: UBERON_0000924

Genotyping

Karyotyping (Cell Line)
Has the cell line karyotype been analysed?	Yes 46, XX no abnormalities detected Passage number: 20
Other Genotyping (Cell Line)